well, don't think it did us much harm to enter this arrangement, which, btw we're still in. bought us a lot of time. More manf research has been completed. CDNF closer to proof of concept. Economy has improved. We've had more time to look elsewhere. Some old funders have recapitalized. AVDX has at least got a shot of turning around. GC found a way to get paid. And in the words of Morpheus, WE ARE STILL HERE!
(1)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links